[December 14, 2017] |
|
Flat-Rate Subscription to Life Science Reports & News Services - Research and Markets
The "Flat-Rate
Subscription to La Merie Publishing Reports & News Services"
newsletter has been added to Research and Markets'
offering.
Flat-Rate Subscription to La Merie Publishing Reports & News
Services
A one-year subscription to this service provides access to:
-
All existing La Merie Publishing reports on stock and listed online in
the store;
-
All new reports released by La Merie Publishing during the term of the
subscription;
-
50 (weekly) issues of R&D Pipeline News
Among these reports are:
-
Competitor Analysis reports in tabular presentation format;
-
Brief Reports; and
-
Full Reports.
Publishing activities include updates of existing reports as well as
release of new reports.
Among La Merie Publishing News & Information Services are:
-
R&D Pipeline News - Technology Edition;
-
R&D Pipeline News - Therapeutic Area Edition.
After purchase of the Flat-Rate Subscription to La Merie Publishing
Reports & News Services, credentials to access a dedicated server
account with the report archive will be provided by e-mail. New issues
of R&D Pipeline News and the R&D and Business Tracking Services will be
delivered by e-mail, old issues are archived in the dedicated server
account.
Coverage of reports:
La Merie Publishing has a special focus on biologics including,
but not limited to:
mRNA vaccines & therapeutics
Oncolytic viruses
Antibody-drug conjugates;
Bispecific antibodies including T-cell or NK cell redirecting
antibodies
CAR & TCR engineered T-cells and NK cells;
Immuno-oncology;
Biosimilar antibodies and proteins
Biosuperior antibodies;
Therapeutic proteins;
Therapeutic and prophylactic vaccines;
Therapeutic peptides.
Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise
information about the pipeline of R&D projects for targets, diseases and
technologies provided in a tabular format and fully referenced.
Full Reports and Brief Reports provide in-depth description and analysis
of targets, pipelines, companies and technologies.
Examples of Full Reports as of October 2017 are:
-
mRNA Vaccines & Therapeutics 2017: an industry analysis of
technologies, pipelines, stakeholders and deals
-
The Oncolytic Virus Landscape 2017: an analysis of pipeline,
stakeholders, deals, industry trends & opportunities
-
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence (News - Alert)
of technologies opens business opportunities beyond CD19 CARTs
-
T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape
analysis of stakeholders, technologies, pipelines and deals
Examples of Brief Reports as of October 2017 are:
-
CD22: a suitable antigen for targeted payload delivery by
immunotherapeutics
-
CD123: a paradigmatic target for immunotherapeutic treatment modalities
-
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment
modalities
Examples of Competitor Analysis Reports as of October 2017 are:
-
Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017
-
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and
company
-
Tumor Microenvironment Modulation via IDO, TGF-/R, CXCR4, CSF-1R,
CD47-SIRPa, Adenosine, STING & Others
-
Biosimilar and Biosuperior Therapeutic Antibodies
-
PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
-
Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Examples of Vaccine Reports
-
Clostridium Difficile Vaccines and Therapeutics 2016
-
Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals
2017
Examples of Peptide Reports
-
Cancer Peptides
-
Cardiometabolic Peptides
-
Anti-Infective Peptides
-
Cardiovascular Peptides
-
Anti-Inflammatory Peptides
For more information about this newsletter visit https://www.researchandmarkets.com/research/ghjp5d/flatrate?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171214005719/en/
[ Back To TMCnet.com's Homepage ]
|